Listed

Kraig Biocraft Laboratories, Inc.: Form 10-K for the period ended Dec 31, 2025

Filed with the SEC on Mar 30, 2026 and accepted by EDGAR at Mar 30, 2026, 17:38 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2025-01-01 to 2025-12-31$165.8kus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2025-01-01 to 2025-12-31−$3.4mus-gaap:OperatingIncomeLoss
Interest expense12 months2025-01-01 to 2025-12-31$570.7kus-gaap:InterestExpenseNonoperating
Net income12 months2025-01-01 to 2025-12-31−$3.6mus-gaap:NetIncomeLoss
Diluted EPS12 months2025-01-01 to 2025-12-31$0.00us-gaap:EarningsPerShareDiluted
Basic EPS12 months2025-01-01 to 2025-12-31$0.00us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2025-01-01 to 2025-12-311,059,485,670 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2025-01-01 to 2025-12-31−$1.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2025-01-01 to 2025-12-31$5.4kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2025-12-31$1.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-12-31$1.9mus-gaap:AssetsCurrent
Total assetsAt period end2025-12-31$2.6mus-gaap:Assets
Current liabilitiesAt period end2025-12-31$10.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-12-31$10.6mus-gaap:Liabilities
Shareholders' equityAt period end2025-12-31−$8.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-26-013630. Last ingested by Listed: Oct 24, 2026, 15:09 ET. Listed shows no prices and gives no investment advice.